Article · Volume 14, Issue 1 · pp. 173–176
Evaluating Quality Adjusted Life in Acute Ischemic Stroke Patients: Insights from Door-to-Needle Time Observations
Balaprasath Balaji1, Aswathee Sivakumar1, Abin Benny1, Boobalan Ramalingam1, Dhanu Veera Pandian2, Arun Shivaraman3, Sengottuvelu Singaravel1, Sheik Haja Sherief1, Duraisami D1
- 1Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, Tamil Nadu, INDIA.
- 2Clinical Pharmacist, NG Hospital and Research Centre, Coimbatore, Tamil Nadu, INDIA.
- 3Consultant Neurologist, NG Hospital and Research Centre, Coimbatore, Tamil Nadu, INDIA.
Abstract
Aim/Background: To assess the safety and effectiveness of tenecteplase in acute ischemic stroke patients treated within 3.5 hr of symptom on set, evaluating its potential as a cost-effective treatment option.Materials and Methods: Study population: 38 patients over 35 years old, Demographics: Predominantly male (62.5%), age range 56-65 years, Lifestyle analysis: 58.3% smokers, 44.7% alcohol consumers, Treatment: Tenecteplase administered within 3.5 hr of symptom onset.Results: Patient Outcomes: 94.73% achieved independence in daily activities; 56.25% experienced shorter hospital stays (3-5 days); 81.05% positive outcomes at discharge; 94.21% improvement after one month; Quality-Adjusted Life Year (QALY) analysis showed significant improvement; Demonstrated cost-effectiveness compared to other thrombolytic treatments.Conclusion: Tenecteplase emerges as a safe and cost-effective treatment for Acute Ischemic Stroke, demonstrating significant improvements in neurological recovery, patient independence, and potential reduction in healthcare costs while enhancing patient quality of life.
Keywords: Tenecteplase; Acute Ischemic Stroke; Quality-Adjusted Life Year (QALY); Neurological Alcohol consumptionrecovery; Alcohol consumption
The full text of this article is available as a PDF. Open the PDF.